Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab 4-year extension study in moderate to severe chronic plaque psoriasis
2012-000985-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of secukinumab in psoriasis and plaque psoriasis (2 arms), sponsored by Novartis. Primary endpoint: Incidence of adverse events. Started Jul 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2012-000985-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000985-39.